New combo aims to stall aggressive brain tumors when surgery and radiation fail
NCT ID NCT06126588
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase IIb trial tests whether combining the drug everolimus with a targeted radiation therapy (177Lu-DOTATATE) can slow tumor growth in people with grades 2 and 3 meningioma that no longer responds to surgery or radiation. About 28 adults will receive the combination for 7 months. The main goal is to see how long the tumor stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
everolimus and 177Lu-DOTATATE
What this could lead to
If successful, this combination could offer a new treatment option that slows tumor growth and extends survival for people with aggressive, hard-to-treat meningioma.
What could go wrong
This is a small, early-phase trial with only 28 participants. The combination may not work better than existing options, and side effects from the drugs could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHRU of Nancy
NOT_YET_RECRUITINGVandœuvre-lès-Nancy, Grand Est, 54511, France
Contact
Contact Email: •••••@•••••
Contact
Contact
-
Nancy Hospital
RECRUITINGVandœuvre-lès-Nancy, 54511, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••